http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2688963-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f220ff41ebe4c7f2e7da8ec7e7e9dca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate | 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b204b8247008af11a5f8ea5d9c61ec08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f861e00cb74d8ba8b83b432096cdf81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6408fa74a92bd3f4361fb0131f4f36ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30a8c38f2891d8dc50dd785d44722309 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eff3c8bf31d4a35aa91df0d62d48fe1 |
| publicationDate | 2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2688963-C1 |
| titleOfInvention | Method for surgical management of rhegmatogenous retinal detachment with removal of internal limiting membrane |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, specifically to ophthalmology. Surgical treatment of rhegmatogenous retinal detachment involves subtotal vitrectomy, introduction of vitreous solution into body cavity in direction of macular area and 1–2 ml of perfluororganic compound (PFOC), removal of residues of dye and colored ILM. Dye used is MembraneBlue-Dual. After reaching the imaging of the internal limiting membrane, it is removed by fragments using intravitreal tweezers in a circular motion at a tangent to the retinal surface from the area of the lower temporal arcade towards the macular area with area of 3–3.5 of the diameter of the optic disc, PFOC is introduced to lower border of available retinal rupture localized on middle periphery. That is followed by draining the subretinal fluid, and then replacing PFOC with air. That is followed by endolaser coagulation of retina in 2–4 rows in staggered order at 0.15–0.18 mWt along the edges of all available peripheral retinal ruptures. Operation is completed by plugging the vitreal cavity with silicone oil. n EFFECT: method provides reducing traumatism of the surgical intervention, improving or preserving visual functions, reducing a risk of forming an epiretinal membrane (ERM) and a cystic macular edema in the postoperative period. n 1 cl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2742758-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2720528-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2777738-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2774600-C2 |
| priorityDate | 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.